EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of farnesol orally and topically against experimental cutaneous leishmaniasis: In -vivo analysis

Harshita Sharma, Rakesh Sehgal iD, Sanjay Jhacak, Kirti Deshmukh, Ritambhara Nada

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0290297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Harshita Sharma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Parasitology, PGIMER, Chandigarh, India. Hauptthemen laut MEDLINE: Leishmaniasis, Cutaneous, Leishmania. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leishmaniasis is a zoonotic disease transmitted by an obligate intra-macrophage protozoan of the genus Leishmania through the infective bite of a vector sandfly. This study investigated the therapeutic efficacy of farnesol, a sesquiterpene compound, for the treatment of cutaneous leishmaniasis (CL) using in vivo BALB/c mouse model. In this study, farnesol’s efficacy was compared with the standard drug, paromomycin. It was observed that farnesol significantly reduced lesion sizes and footpad thickness compared to the control group (paromomycin). Lymph node size was also significantly reduced in farnesol-treated mice, indicating its ability to control infection spread. Combination therapy with farnesol and Paromomycin did not demonstrate synergistic effects. These results highlight the potential of farnesol as an alternative therapeutic agent for CL. Further investigations are required to elucidate its mechanism of action and assess potential off-target effects. Optimization of oral delivery methods should be explored to enhance bioavailability. Overall, our findings support farnesol’s efficacy in CL treatment, offering promising prospects for improved disease management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leishmaniasis, CutaneousLeishmaniaAnimalsMiceFarnesolParomomycinAdministration, CutaneousMice, Inbred BALB C

Substanzen

FarnesolParomomycin

Autor:innen und Institutionen

  • Department of Medical Parasitology, PGIMER, Chandigarh, India.
  • Department of Natural Products, NIPER, Mohali, India.
  • Department of Histopathology, PGIMER, Chandigarh, India.

ORCID-Profile: Rakesh Sehgal

Zitieren

APA

Sharma, H., Sehgal, R., Jhacak, S., Deshmukh, K., & Nada, R. (2023). Evaluation of farnesol orally and topically against experimental cutaneous leishmaniasis: In -vivo analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0290297

Vancouver

Sharma H, Sehgal R, Jhacak S, Deshmukh K, Nada R. Evaluation of farnesol orally and topically against experimental cutaneous leishmaniasis: In -vivo analysis. PLOS ONE. 2023. doi:10.1371/journal.pone.0290297

BibTeX
@article{Sharma2023,
  author = {Sharma, Harshita and Sehgal, Rakesh and Jhacak, Sanjay and Deshmukh, Kirti and Nada, Ritambhara},
  title = {Evaluation of farnesol orally and topically against experimental cutaneous leishmaniasis: In -vivo analysis},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0290297}
}
Kostenlos starten →